atomoxetine hydrochloride has been researched along with Body Weight in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (66.67) | 29.6817 |
| 2010's | 3 (25.00) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, J; Chen, L; Cheng, Q; Deng, L; Li, T; Yang, T; Zhang, Y; Zhao, Q; Zhou, P; Zhu, L | 1 |
| Arcieri, R; Bonati, M; Chiarotti, F; Germinario, EA; Masi, G; Panei, P; Vella, S; Zuddas, A | 1 |
| Ball, MP; Buchanan, RW; Feldman, S; Kelly, DL; McMahon, RP; Warren, KR | 1 |
| Gabriel, A; Violato, C | 1 |
| Kratochvil, CJ; Wernicke, JF | 1 |
| Perry, CM; Simpson, D | 1 |
| Adler, LA; Michelson, D; Milton, DR; Moore, RJ; Spencer, TJ | 1 |
| Allen, AJ; Coffey, BJ; Dunn, DW; Dure, LS; Erenberg, G; Feldman, PD; Gilbert, DL; Kelsey, DK; Kurlan, RM; Layton, LL; Lewis, DW; Linder, SL; Milton, DR; Mintz, MI; Ricardi, RK; Sallee, FR; Spencer, TJ; Winner, PK | 1 |
| Allen, C; Pitcock, J | 1 |
| Maynard, M; McDougle, CJ; Posey, DJ; Stigler, KA; Wiegand, RE; Wilkerson, J | 1 |
| Guerdjikova, A; Hudson, JI; Keck, PE; Kotwal, R; Lake, KA; McElroy, SL; Nelson, EB; Welge, JA | 1 |
| Allen, AJ; Bailey, CE; Casat, CD; Dunn, DW; Feldman, PD; Furr, AJ; Geller, DA; Jain, R; Kratochvil, CJ; Lipetz, RS; Newcorn, JH; Ruff, DD; Sangal, RB; Saylor, KE; Spencer, TJ | 1 |
3 review(s) available for atomoxetine hydrochloride and Body Weight
| Article | Year |
|---|---|
Safety profile of atomoxetine in the treatment of children and adolescents with ADHD.
Topics: Adolescent; Age Factors; Antidepressive Agents; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Blood Pressure; Body Weight; Child; Clinical Trials as Topic; Cytochrome P-450 CYP2D6; Electrocardiography; Feeding and Eating Disorders; Headache; Humans; Placebos; Propylamines; Pulse; Treatment Outcome | 2002 |
Atomoxetine.
Topics: Adolescent; Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Biological Availability; Body Weight; Child; Drug Administration Schedule; Half-Life; Humans; Intestinal Absorption; Propylamines; Randomized Controlled Trials as Topic; Tissue Distribution | 2003 |
Close up on atomoxetine: a nonstimulant choice for treating ADHD.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Body Weight; Central Nervous System Stimulants; Chemical and Drug Induced Liver Injury; Child; Choice Behavior; Drug Administration Schedule; Drug Interactions; Drug Labeling; Humans; Nursing Assessment; Patient Selection; Practice Guidelines as Topic; Propylamines; Risk Factors; Suicide; Treatment Outcome | 2006 |
5 trial(s) available for atomoxetine hydrochloride and Body Weight
| Article | Year |
|---|---|
Placebo-controlled trial of atomoxetine for weight reduction in people with schizophrenia treated with clozapine or olanzapine.
Topics: Adrenergic Uptake Inhibitors; Adult; Antipsychotic Agents; Appetite Depressants; Atomoxetine Hydrochloride; Attention; Benzodiazepines; Body Mass Index; Body Weight; Brief Psychiatric Rating Scale; Clozapine; Combined Modality Therapy; Diet, Reducing; Double-Blind Method; Exercise; Female; Humans; Life Style; Male; Maryland; Middle Aged; Neuropsychological Tests; Obesity; Olanzapine; Propylamines; Psychotic Disorders; Schizophrenia | 2011 |
Adjunctive atomoxetine to SSRIs or SNRIs in the treatment of adult ADHD patients with comorbid partially responsive generalized anxiety (GA): an open-label study.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Anxiety Disorders; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Blood Pressure; Body Weight; Drug Resistance; Drug Therapy, Combination; Female; Heart Rate; Humans; Male; Middle Aged; Propylamines; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors | 2011 |
Long-term, open-label study of the safety and efficacy of atomoxetine in adults with attention-deficit/hyperactivity disorder: an interim analysis.
Topics: Adult; Age Factors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Blood Pressure; Body Weight; Erectile Dysfunction; Female; Headache; Heart Rate; Humans; Longitudinal Studies; Male; Patient Dropouts; Placebos; Propylamines; Psychiatric Status Rating Scales; Treatment Outcome; Xerostomia | 2005 |
Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders.
Topics: Adolescent; Adrenergic Agonists; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Body Weight; Child; Comorbidity; Double-Blind Method; Female; Heart Rate; Humans; Male; Placebo Effect; Propylamines; Tachycardia; Tic Disorders; Treatment Outcome | 2005 |
Atomoxetine in the treatment of binge-eating disorder: a randomized placebo-controlled trial.
Topics: Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; Body Mass Index; Body Weight; Bulimia Nervosa; Double-Blind Method; Female; Humans; Male; Middle Aged; Propylamines; Treatment Outcome | 2007 |
4 other study(ies) available for atomoxetine hydrochloride and Body Weight
| Article | Year |
|---|---|
Methylphenidate and atomoxetine treatment negatively affect physical growth indexes of school-age children and adolescents with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Body Height; Body Mass Index; Body Weight; Central Nervous System Stimulants; Child; China; Female; Humans; Male; Methylphenidate; Schools; Time Factors | 2021 |
Attention-deficit/hyperactivity disorder drugs and growth: an Italian prospective observational study.
Topics: Adolescent; Adolescent Development; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Body Height; Body Weight; Central Nervous System Stimulants; Child; Child Development; Female; Humans; Italy; Male; Methylphenidate; Propylamines; Prospective Studies; Registries | 2013 |
Open-label atomoxetine for attention-deficit/ hyperactivity disorder symptoms associated with high-functioning pervasive developmental disorders.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Asperger Syndrome; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Autistic Disorder; Body Weight; Child; Child Development Disorders, Pervasive; Comorbidity; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Intelligence; Irritable Mood; Male; Neuropsychological Tests; Pilot Projects; Propylamines; Prospective Studies; Treatment Outcome | 2006 |
Effects of atomoxetine on growth in children with attention-deficit/hyperactivity disorder following up to five years of treatment.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Body Height; Body Mass Index; Body Weight; Child; Female; Growth; Humans; Longitudinal Studies; Male; Propylamines; Psychiatric Status Rating Scales | 2007 |